Aim immunotech announces completion of enrollment in phase 2 study evaluating ampligen® for the treatment of post-covid conditions

Ocala, fla., aug. 08, 2023 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim”) today announced the completion of enrollment in the company's phase 2 study evaluating ampligen® as a potential therapeutic for people with post-covid conditions (“amp-518”).
AIM Ratings Summary
AIM Quant Ranking